Swiss pharmaceutical company Sandoz filed an anti-dumping complaint with the European Union on May 27 against Chinese imports of the antibiotic active pharmaceutical ingredient amoxicillin [1]. The complaint challenges below-cost pricing and government subsidies from China that Sandoz says distort the market and threaten European antibiotic production [2, 3, 4, 5, 1].
Sandoz is among the world's largest generic drug producers and is the only European company with a fully integrated penicillin drug production network [1]. CEO Richard Saynor highlighted that about 90% of global antibiotic active ingredients are made outside Europe, primarily in China. "This is a crucial strategic vulnerability," Saynor said, adding that current market conditions systematically disadvantage resilient European producers and risk the loss of critical manufacturing capacity [2].
The complaint marks the first anti-dumping case in the pharmaceutical sector in decades [2, 3, 4, 5, 1]. Sandoz argues the unfair pricing and subsidies are making local European production noncompetitive, endangering the independent supply of essential antibiotics.
Saynor emphasized the wider stakes: "Ensuring antibiotic supply is not only a health policy matter but also one of economic security and strategic trade." He called for immediate EU action to safeguard independent antibiotic manufacturing for years to come [1].
The filing may prompt the EU to investigate the pricing and trade practices related to Chinese antibiotic exports. Sandoz’s complaint brings urgent attention to risks posed by heavy European reliance on imports.
The complaint was officially filed on May 27, with multiple news outlets reporting on it and Sandoz statements on May 28 [3, 4, 5].
